drugset / Trial / NCT05892432
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
Phase 2
Completed
50 enrolled
University of Colorado, Denver
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
This study is a randomized controlled trial of oral semaglutide among treatment-seeking individuals with AUD. The investigators will randomly assign 50 participants to receive semaglutide (titrated to 7 milligrams (mg) per day) or matched placebo for 8 weeks. The primary aims are to assess the safety and tolerability of semaglutide in this population and to evaluate its effects, relative to placebo, on alcohol cue-elicited craving and alcohol consumption.
Timeline
- Start
- 2024-01-11
- Primary completion
- 2025-11-04
- Completion
- 2025-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Semaglutide | Peptide | 7 mg | Oral |